CompanyGraph
Tong Ren Tang Technologies Co., Ltd.
1666 · HKEX · China
Price data from its TNG listing on XSTU, quoted in EUR
tongrentangkj.comFinancials as of FY2025
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleRevenue is $860.16M, above the global median of $548.88M
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
6.69%Above 5Y avg (3.71%)
Annual Rate
HKD 0.21Paid annual
Payout Ratio
74.7%Moderate
Payback Period
1.6 yr
Last Ex-Dividend
Jun 16, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.07BHKD773.86M · vs all stocks (USD)
Trailing P/E
11.02xRevenue (TTM)
6.75BHKD860.16M · vs all stocks (USD)
Profit Margin
5.32%Beta
0.7690xvs all stocks
52-Week Change
-36.52%vs all stocks
Market Capitalization
6.07BHKD773.86M · vs all stocks (USD)
Enterprise Value
4.33BHKD551.66M · vs all stocks (USD)
Trailing P/E
11.02xForward P/E
6.59xPrice to Sales (TTM)
0.6848xPrice to Book (MRQ)
0.4625xEnterprise to Revenue
0.6410xEnterprise to EBITDA
4.29xProfit Margin
5.32%Operating Margin
14.19%Return on Assets (TTM)
2.96%Return on Equity (TTM)
5.21%Revenue (TTM)
6.75BHKD860.16M · vs all stocks (USD)
Revenue per Share (TTM)
4.50HKDUpdated Sep 20, 2026Quarterly Revenue Growth
-19.10%Gross Profit (TTM)
2.49BHKD317.22M · vs all stocks (USD)
EBITDA (TTM)
1.22BHKD154.90M · vs all stocks (USD)
Net Income (TTM)
358.75MHKD45.73M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-26.40%Operating Cash Flow (TTM)
1.41BHKD180.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.25BHKD158.79M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2069HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
6.69%vs all stocks
5-Year Average Dividend Yield
3.71%vs all stocks
Payout Ratio
74.71%Minority Interest (Equity)
2.92BCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3100CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.28BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.28BSharesFY2025 · Dec 31, 2025Operating Cash Flow
1.73BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.61BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.70BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
822.42MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-40.55MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
334.45MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
614.43MCNYFY2025 · Dec 31, 2025Capital Expenditures
-116.29MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-93.84MCNYFY2025 · Dec 31, 2025Sale of Investments
200.04MCNYFY2025 · Dec 31, 2025Other Investing Activity
-12.16MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-22.25MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.24BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.65BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-228.27MCNYFY2025 · Dec 31, 2025Other Financing Charges
6.06MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-631.78MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.28BSharesUpdated Sep 20, 2026Float Shares
585.32MSharesUpdated Sep 20, 2026% Held by Insiders
6.90%vs all stocks
% Held by Institutions
15.47%vs all stocks
Total Cash (MRQ)
5.85BHKD746.09M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.91HKDUpdated Sep 20, 2026Total Debt (MRQ)
2.23BHKD284.85M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1901xCurrent Ratio (MRQ)
5.08xBook Value per Share (MRQ)
6.67HKDUpdated Sep 20, 2026Total Assets
13.71BCNY2.05B · vs all stocks (USD)
Total Current Assets
10.19BCNYFY2025 · Dec 31, 2025Total Liabilities
3.45BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.52BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.67BCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.78BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.70BCNYFY2025 · Dec 31, 2025Other Short-term Investments
129.39MCNYFY2025 · Dec 31, 2025Accounts Receivable
670.32MCNYFY2025 · Dec 31, 2025Inventory
4.55BCNYFY2025 · Dec 31, 2025Accounts Payable
666.03MCNYFY2025 · Dec 31, 2025Short-term Debt
459.70MCNYFY2025 · Dec 31, 2025Long-term Debt
1.54BCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.28BCNYFY2025 · Dec 31, 2025Retained Earnings
4.46BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
10.26BCNY1.53B · vs all stocks (USD)
52-Week Low
2.96HKDUpdated Sep 20, 202652-Week High
4.95HKDUpdated Sep 20, 202652-Week Change
-36.52%vs all stocks
Beta
0.7690xvs all stocks
50-Day MA
3.32HKDUpdated Sep 20, 2026200-Day MA
3.85HKDUpdated Sep 20, 2026Avg 10-Day Volume
1.10MSharesUpdated Sep 20, 2026Avg 30-Day Volume
1.93MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.2800HKDUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Revenue is $860.16M, above the global median of $548.88MNotable
Revenue (USD): 860,159,279.931Global Median: 548,883,780.48
Levered free cash flow is $158.79M, above the global median of $18.73MNotable
Levered free cash flow (USD): 158,786,853.819Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vireo Growth Inc.
Tier 1ProductionApproval-Gated PipelineFlowInterface
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Duorui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Olema Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule